Latest news with #ABBIE
Associated Press
02-05-2025
- Business
- Associated Press
Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization
CHINO HILLS, CA / ACCESS Newswire / May 2, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces Dr. Leonardo Mirandola joined the Company as Advisory Board Member. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, will spearhead the company's initiatives to advance its CAR-T cell projects toward clinical trials. Dr. Mirandola brings a wealth of expertise in operational management, R&D, and clinical development, with a proven track record in transforming innovative scientific breakthroughs into viable treatment options. He holds a Ph.D. and a Master's degree from the University of Milano, Italy. 'Dr. Mirandola's extensive background in cell therapy and his remarkable success in clinical translation make him an invaluable addition to our team,' said David Aguilar of SOHM Inc. 'His leadership will be instrumental as we push the boundaries of CAR-T cell production and therapy and strive to bring new treatment options to those battling cancer.' Before joining SOHM Inc., Dr. Mirandola served as Chief Scientific Officer and Interim Chief Operations Officer at Kiromic Biopharma, where he played a pivotal role in developing and overseeing clinical operations for various groundbreaking therapies. His contributions led to the advancement of an autologous dendritic cell therapeutic vaccine for solid tumors and an allogeneic gamma-delta T-cell therapy, which has received Fast-Track-designation by the FDA and showed positive results in Phase 1 trials for patients with Stage 4 non-small cell lung cancer. Dr. Mirandola has a remarkable record of securing patents for novel manufacturing techniques and AI-driven target discovery processes, which have significantly advanced the understanding and development of cell therapies. His leadership in establishing cGMP-compliant manufacturing processes will be critical as SOHM Inc. prepares its CAR-T cell projects for rigorous clinical evaluation. 'I am excited to join SOHM Inc. and collaborate with such a talented team dedicated to making a difference in the lives of cancer patients,' said Dr. Mirandola. SOHM, Inc. is harnessing the power of ABBIE, its proprietary gene editing platform, to accelerate and enhance the commercialization of CAR-T cell therapies. Unlike traditional viral-based or CRISPR systems, ABBIE offers a cost-efficient editing approach that significantly reduces manufacturing complexity and regulatory hurdles. By integrating ABBIE into its CAR-T development pipeline, SOHM aims to streamline production timelines, improve genetic payload fidelity, and broaden the therapeutic window - ultimately making advanced cell therapies more accessible and scalable for a wider range of cancer patients. For further information on SOHM Inc. and its latest advancements in biotechnology, please visit ( ). About SOHM, Inc.: SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery. For further information regarding this announcement or to explore potential collaborations, please contact: SOHM, Inc.: Name: Baron Night, CEO/Dr. David Aguilar, COO Email: [email protected] Phone: (714) 522-6700 Safe Harbor Statement: This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on SOURCE: SOHM, Inc press release
Associated Press
28-04-2025
- Business
- Associated Press
SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies
CHINO HILLS, CA / ACCESS Newswire / April 28, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces today its collaboration and licensing agreement with an undisclosed emerging drug development partner. This partnership accentuates SOHM's leadership in gene editing and cell engineering. David Aguilar, PhD, Chief Operating Officer, stated that this collaborative and licensing project will position SOHM and its partners as leaders in microfluidic-based gene editing technology to develop new micro-dosed CAR-T cell therapies to treat cancers. As part of this alliance, our partners are licensing SOHM's proprietary genome editing ABBIE products and methods. This partnership marks a significant leap forward in developing novel genome editing technologies and CAR-T-based therapies poised to revolutionize treatments for cancer and other diseases. SOHM, Inc., is set to receive $6 million upon funding approval by its partners to advance their joint research initiative focused on developing cutting-edge genome editing products. For this initiative, SOHM's groundbreaking ABBIE (A Binding-based Integrase Enzyme) integration system is licensed to enhance autologous CAR-T cells' safe and efficient production, making significant strides toward clinical applications. David Aguilar, PhD, Chief Operating Officer, expressed his enthusiasm for the collaboration: 'This partnership represents a pivotal moment in the pursuit of advanced genome editing technologies. By integrating our ABBIE system with microfluidic gene editing capabilities, we can accelerate research and bring innovative, cost-efficient micro-dosed CAR-T treatments to the clinic. Most importantly, our efforts will provide new hope for patients battling cancer.' The proposed project aims to streamline gene editing and CAR-T cell processes, making them more accessible and effective for therapeutic applications. By combining SOHM's proprietary integration system with our partners' cutting-edge technology under the license, the collaborators aspire to set new standards in the fields of CAR-T cell therapy and genome editing, significantly impacting the treatment of various diseases and improving overall patient care. As advancements in genome editing and delivery systems continue to evolve, SOHM, Inc. and its partners are committed to leading the charge in transforming how genetic disorders, especially cancer, are approached. This collaboration signifies a crucial step towards integrating revolutionary technology into clinical practice, ultimately enhancing the future of biotechnology. For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit About SOHM, Inc.: SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery. For further information regarding this announcement or to explore potential collaborations, please contact: SOHM, Inc.: Name: Baron Night, CEO/Dr. David Aguilar, COO Email: [email protected] Phone: (714) 522-6700 Safe Harbor Statement: This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on SOURCE: SOHM, Inc press release
Associated Press
10-03-2025
- Business
- Associated Press
SOHM, Inc. Shares Groundbreaking Findings in ABBIE Technology
CHINO HILLS, CA / ACCESS Newswire / March 10, 2025 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, has announced today Groundbreaking findings in their ABBIE Technology. Dr. David Aguilar, Chief Operating Officer, states that we are thrilled to share some exciting advancements in our ABBIE development and commercialization journey! Our team has made significant strides, leading us to refine our strategy for the future. After careful consideration, we have decided to pivot away from the sale and distribution of ABBIE kits for independent use. Instead, we are harnessing the power of our expanding global Intellectual Property portfolio to establish a strong and innovative licensing model. This strategic shift enables us to focus our marketing and sales efforts on forging valuable licensing partnerships in the dynamic fields of CAR-T therapy, cancer drug development and gene therapy. We are currently engaged in in-depth technical diligence discussions with both small-scale innovators and major, globally positioned pharmaceutical companies, positioning ABBIE at the forefront of cutting-edge cancer research. Our recent findings are particularly groundbreaking: ABBIE technology provides an inherent traceability component that is currently absent in competing technologies. This capability not only enhances the safety and control of therapies but also streamlines the process for FDA filings and approval requirements. We are on the brink of a new era in personalized medicine, where traceability will be a cornerstone of therapeutic efficacy and patient safety. As we look to the future, we are excited to announce that we expect to publish our groundbreaking findings in the second quarter of 2025. Additionally, we are planning a series of platform seminars that will delve into the intricacies of our technology, showcasing its potential to revolutionize cancer treatment. The possibilities are boundless, and we are eager to continue this journey together, paving the way for transformative advancements in healthcare! Stay tuned for more updates as we embark on this thrilling path forward. Dr. Aguilar explained. About SOHM, Inc.: SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. To learn more about SOHM, Inc., visit SOHM, Inc.: Name: Baron Night, CEO/Dr. David Aguilar, COO Phone: (714) 522-6700 Safe Harbor Statement: This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on
